EGFR and non-small cell lung carcinoma: To address this critical evidence gap, we conducted a comprehensive Bayesian network meta‐analysis (NMA), which is the first study to evaluate the comparative efficacy and safety of third‐gen TKI monotherapies in advanced, treatment‐naive, EGFR‐mutated NSCLC.